Recent U.S. Customs and Border Protection rulings from CROSS, searchable by HTS code, keyword, or ruling number.
In your letter dated December 15, 2025, you requested a tariff classification ruling. Venlafaxine HCL, imported in 37.5 mg, 75 mg, and 150 mg extended-release capsules, is in a class of medications called selective serotonin and norepinephrine reuptake inhibitors (SNRIs). It is indicated for the management of major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder (SAD) and panic disorder (PD).
In your letter dated December 3, 2025, you requested a tariff classification ruling. Fluvoxamine Maleate, imported in 100 mg and 150 mg extended-release capsules, belongs to a group of medicines known as selective serotonin reuptake inhibitors (SSRIs). It is indicated for the treatment of obsessive compulsive disorder (OCD).
Source: rulings.cbp.gov (CROSS). This index holds New York rulings from the recent period and the Headquarters rulings they cite. It is not the full CROSS database of 222,467 rulings, and it does not hold every Headquarters ruling. New rulings usually appear here within a few days of CBP publishing them; a ruling published long after its number was assigned can take several weeks. Revoked, modified and proposed marks come from the weekly Customs Bulletin, where CBP publishes most such actions under 19 U.S.C. 1625(c), read here from the Nov 2024 issues onward, and from the subjects of indexed Headquarters rulings. A revocation is marked from the date it takes effect. The absence of a mark is not confirmation that a ruling is still in effect. A ruling letter is binding on CBP only for the particular transaction or issue it describes (19 CFR 177.9). Confirm the text and status on CROSS before relying on a ruling. Not legal advice.